Russell Johnson
Executive Director, Delivery Sciences Moderna
Seminars
Thursday 4th June 2026
Roundtable Discussion: Discussing Targeted LNP Design to Minimize Immunogenicity, Maximize Safety, & Protect Sensitive Tissues for Extrahepatic Applications
2:00 pm
- How can lipid chemistry and functional group modifications be leveraged to reduce toxicity and off-target effects while maintaining delivery efficiency?
- Which design strategies and targeting ligand modifications best balance tissue specificity, immunogenicity, and safety across sensitive extrahepatic targets?
- How can LNP formulations be engineered to mitigate immune recognition and anti-drug antibody formation to achieve tolerable repeat dosing?
Wednesday 3rd June 2026
Panel Discussion: Exploring the Future of Extrahepatic LNPs to Overcome Delivery Barriers, Expand Therapeutic Reach, & Unlock Novel Disease Treatments
2:15 pm
- What are the remaining barriers for achieving efficient, organ-specific delivery to difficult targets?
- Which design strategies and technologies are most promising for enabling precise extrahepatic targeting while minimizing liver accumulation?
- What unmet therapeutic needs could next-generation extrahepatic LNPs address to expand the RNA, gene editing, and cell therapy landscape?
